[go: up one dir, main page]

MA35035B1 - Anticorps polypeptidiques qui antagonisent les cd40 - Google Patents

Anticorps polypeptidiques qui antagonisent les cd40

Info

Publication number
MA35035B1
MA35035B1 MA36322A MA36322A MA35035B1 MA 35035 B1 MA35035 B1 MA 35035B1 MA 36322 A MA36322 A MA 36322A MA 36322 A MA36322 A MA 36322A MA 35035 B1 MA35035 B1 MA 35035B1
Authority
MA
Morocco
Prior art keywords
polypeptide antibodies
antagonize
polypeptide
domain
antibodies according
Prior art date
Application number
MA36322A
Other languages
English (en)
Inventor
Anish Suri
Steven Sheriff
Suzanne Suchard
Aaron Yamniuk
Stanley Krystek
James Tamura
James Bryson
Steven Grant
Philip Drew
Original Assignee
Bristol Myers Squibb Co
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35035(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co, Domantis Ltd filed Critical Bristol Myers Squibb Co
Publication of MA35035B1 publication Critical patent/MA35035B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Les anticorps polypeptidiques selon l'invention se lient spécifiquement à un nouvel épitope de CD40 humain. Ces anticorps polypeptidiques n'ont pas d'activités agonistes des CD40. Ils sont utiles dans le traitement de maladies impliquant l'activation des CD40, telles que les maladies auto-immunes. Les anticorps polypeptidiques selon l'invention peuvent être des anticorps de type domaine (dAb) comprenant un seul domaine VL ou VH. La demi-vie des anticorps polypeptidiques selon l'invention peut être augmentée par modification des anticorps polypeptidiques pour qu'ils soient des réactifs bispécifiques pouvant également se lier à la sérumalbumine humaine (HSA).
MA36322A 2011-04-21 2012-04-20 Anticorps polypeptidiques qui antagonisent les cd40 MA35035B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477904P 2011-04-21 2011-04-21
PCT/US2012/034519 WO2012145673A1 (fr) 2011-04-21 2012-04-20 Anticorps polypeptidiques qui antagonisent les cd40

Publications (1)

Publication Number Publication Date
MA35035B1 true MA35035B1 (fr) 2014-04-03

Family

ID=46000407

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36322A MA35035B1 (fr) 2011-04-21 2012-04-20 Anticorps polypeptidiques qui antagonisent les cd40

Country Status (35)

Country Link
US (3) US9475879B2 (fr)
EP (2) EP2699601B1 (fr)
JP (2) JP6114256B2 (fr)
KR (2) KR101905346B1 (fr)
CN (2) CN106977604A (fr)
AR (1) AR086360A1 (fr)
AU (2) AU2012245309C1 (fr)
BR (1) BR112013026828A2 (fr)
CA (1) CA2833743A1 (fr)
CL (1) CL2013003043A1 (fr)
CO (1) CO6801649A2 (fr)
CY (1) CY1120637T1 (fr)
DK (1) DK2699601T3 (fr)
EA (1) EA030851B1 (fr)
ES (1) ES2664619T3 (fr)
HR (1) HRP20180571T1 (fr)
HU (1) HUE038848T2 (fr)
IL (1) IL228720B (fr)
LT (1) LT2699601T (fr)
MA (1) MA35035B1 (fr)
ME (1) ME03071B (fr)
MX (1) MX354243B (fr)
MY (1) MY165090A (fr)
NO (1) NO2699601T3 (fr)
PE (1) PE20141188A1 (fr)
PH (1) PH12013502013B1 (fr)
PL (1) PL2699601T3 (fr)
PT (1) PT2699601T (fr)
RS (1) RS57087B1 (fr)
SG (1) SG194561A1 (fr)
SI (1) SI2699601T1 (fr)
SM (1) SMT201800228T1 (fr)
TN (1) TN2013000417A1 (fr)
TW (2) TWI598363B (fr)
WO (1) WO2012145673A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
NO2699601T3 (fr) 2011-04-21 2018-06-16
US8778345B2 (en) 2011-04-29 2014-07-15 Apexigen, Inc. Anti-CD40 antibodies
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
CN110066335B (zh) * 2012-10-30 2024-04-05 埃派斯进有限公司 抗-cd40抗体及其使用方法
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
CN107249318A (zh) 2014-12-10 2017-10-13 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN107207601A (zh) 2015-01-20 2017-09-26 Igm生物科学股份有限公司 肿瘤坏死因子(tnf)超家族受体结合分子及其应用
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
US20190016818A1 (en) * 2015-05-27 2019-01-17 La Jolla Biologics, Inc. Antibodies against glypican-3 and their uses in cancer diagnosis and treatment
UY36692A (es) 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
US20190086405A1 (en) 2016-03-16 2019-03-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
EP3471754A1 (fr) 2016-06-20 2019-04-24 Kymab Limited Anticorps anti-pd-l1
KR102019033B1 (ko) 2016-11-11 2019-09-06 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
EP3555134A2 (fr) 2016-12-19 2019-10-23 Glenmark Pharmaceuticals S.A. Nouveaux agonistes de tnfr et leurs utilisations
KR20190132665A (ko) * 2017-03-23 2019-11-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-C5a 항체 및 이의 용도
AU2018271915B2 (en) 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
CN110637035A (zh) * 2017-05-25 2019-12-31 百时美施贵宝公司 经修饰的IgG1 Fc结构域与抗-CD40域抗体的融合
CN110621697B (zh) 2017-05-25 2023-06-27 百时美施贵宝公司 拮抗性cd40单克隆抗体及其用途
WO2018222711A2 (fr) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprenant une combinaison d'un anticorps anti-lag-3, d'un inhibiteur de voie pd-1 et d'un agent immunothérapeutique
BR112019025048A2 (pt) * 2017-06-01 2020-06-30 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd40, fragmento de ligação ao antígeno do mesmo, e uso médico dos mesmos
CA3103629A1 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activite immunitaire par modulation de facteurs de signalisation post-cellulaires
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
US20240254248A1 (en) 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
AU2019389354A1 (en) 2018-11-30 2021-07-15 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment and pharmaceutical use thereof
US20220135694A1 (en) * 2019-02-01 2022-05-05 Lava Therapeutics B.V. Novel cd40-binding antibodies
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
US20210032356A1 (en) * 2019-08-02 2021-02-04 Eastern Virginia Medical School Method for treating seizures
EP4076434A1 (fr) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
BR112022012191A2 (pt) 2019-12-20 2022-12-13 Amgen Inc Construtos de anticorpos multiespecíficos agonistas de cd40 visados à mesotelina para o tratamento de tumores sólidos
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11862306B1 (en) 2020-02-07 2024-01-02 Cvs Pharmacy, Inc. Customer health activity based system for secure communication and presentation of health information
JP2023523016A (ja) * 2020-04-23 2023-06-01 アルファ・ベータ・ホールディングス，リミテッド・ライアビリティ・カンパニー がんを処置するための組成物および方法
CN115867580A (zh) 2020-05-18 2023-03-28 百时美施贵宝公司 具有改进的药代动力学特性的抗体变体
CA3184366A1 (fr) 2020-06-29 2022-01-06 Darby Rye Schmidt Virus modifies pour favoriser la thanotransmission et leur utilisation dans le traitement du cancer
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (fr) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Cellules immunitaires modifiées pour favoriser la thanotransmission de phényléthanolamines et leurs utilisations
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
CN114149508B (zh) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 一种结合cd40l的融合蛋白及其应用
WO2023170606A1 (fr) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
EP4598946A1 (fr) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
KR20250057233A (ko) 2023-10-20 2025-04-29 한상진 이동식 무선 자동 제습기
WO2025129007A1 (fr) * 2023-12-15 2025-06-19 Werewool Inc. Fibres d'alginate de soja
WO2025184603A2 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Utilisation d'inhibiteurs de cd40 pour inhiber une réponse immunitaire et permettre une administration et une réadministration d'immunogène
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation
US5247069A (en) 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
CA2089229C (fr) 1992-02-14 2010-04-13 Alejandro A. Aruffo Recepteur cd40cr et ligands pour celui-ci
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
NZ278740A (en) 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
DE69713499T3 (de) 1996-03-20 2010-05-06 Bristol-Myers Squibb Co., Seattle Verfahren zur inhibierung der immunreaktion durch blockierung der gp39/cd40 und ctla4/cd28/b7 routen und zusammensetzung zu deren verwendung
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
EP1326896B1 (fr) * 2000-10-02 2010-11-24 Novartis Vaccines and Diagnostics, Inc. Anticorps humains diriges contre cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP2149585B1 (fr) * 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Procédés d'utilisation d'anticorps monoclonaux antagonistes anti-CD40
EP1707627B1 (fr) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Mutant antagonistique d'un anticorps anti-CD40
DK1737962T3 (da) 2004-03-24 2010-12-13 Domantis Ltd GAS1-universel leder
MXPA06012430A (es) 2004-04-27 2007-04-19 Novartis Vaccines & Diagnostic Anticuerpos monoclonales antagonistas anti-cd40 y metodos para su uso.
ZA200702427B (en) * 2004-09-17 2008-12-31 Domantis Ltd Compositions monovalent for CD40L binding and methods of use
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
EP1891113A2 (fr) * 2005-06-02 2008-02-27 AstraZeneca AB Anticorps diriges contre cd20 et leurs utilisations
JP2009519718A (ja) 2005-12-16 2009-05-21 ジェネンテック・インコーポレーテッド 抗ｏｘ４０ｌ抗体とその使用方法
KR20080098382A (ko) 2006-01-24 2008-11-07 도만티스 리미티드 Ｉｌ-4 및/또는 ｉｌ-13에 결합하는 리간드
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
RU2487877C2 (ru) * 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
KR20110096553A (ko) * 2008-11-28 2011-08-30 아보트 러보러터리즈 안정한 항체 조성물 및 이의 안정화 방법
HUE049849T2 (hu) 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
NO2699601T3 (fr) * 2011-04-21 2018-06-16

Also Published As

Publication number Publication date
AR086360A1 (es) 2013-12-11
SG194561A1 (en) 2013-12-30
CN103842382A (zh) 2014-06-04
CL2013003043A1 (es) 2014-06-20
HRP20180571T1 (hr) 2018-05-18
MX2013011966A (es) 2014-02-11
IL228720A0 (en) 2013-12-31
AU2012245309A1 (en) 2013-12-12
US20140099317A1 (en) 2014-04-10
CN103842382B (zh) 2017-03-15
JP2017099391A (ja) 2017-06-08
MX354243B (es) 2018-02-20
JP6114256B2 (ja) 2017-04-12
DK2699601T3 (en) 2018-04-23
IL228720B (en) 2018-12-31
CA2833743A1 (fr) 2012-10-26
HUE038848T2 (hu) 2018-11-28
CY1120637T1 (el) 2019-12-11
LT2699601T (lt) 2018-03-26
AU2012245309C1 (en) 2016-07-21
PL2699601T3 (pl) 2018-05-30
BR112013026828A2 (pt) 2016-11-29
PT2699601T (pt) 2018-04-05
EP2699601B1 (fr) 2018-01-17
EP2699601A1 (fr) 2014-02-26
PH12013502013B1 (en) 2018-11-28
KR20170049628A (ko) 2017-05-10
SI2699601T1 (en) 2018-04-30
EP3372616A1 (fr) 2018-09-12
KR101905346B1 (ko) 2018-10-05
AU2016202672B2 (en) 2017-07-20
EA201391564A1 (ru) 2014-02-28
TW201712038A (zh) 2017-04-01
US9475879B2 (en) 2016-10-25
WO2012145673A1 (fr) 2012-10-26
RS57087B1 (sr) 2018-06-29
US20170015754A1 (en) 2017-01-19
TWI598363B (zh) 2017-09-11
AU2016202672A1 (en) 2016-05-26
CN106977604A (zh) 2017-07-25
US20200199244A1 (en) 2020-06-25
TN2013000417A1 (en) 2015-03-30
NO2699601T3 (fr) 2018-06-16
ES2664619T3 (es) 2018-04-20
CO6801649A2 (es) 2013-11-29
ME03071B (fr) 2019-01-20
MY165090A (en) 2018-02-28
SMT201800228T1 (it) 2018-07-17
EA030851B1 (ru) 2018-10-31
PE20141188A1 (es) 2014-09-22
AU2012245309B2 (en) 2016-02-04
US11136406B2 (en) 2021-10-05
KR101734614B1 (ko) 2017-05-12
NZ618025A (en) 2015-10-30
KR20140009505A (ko) 2014-01-22
US10544228B2 (en) 2020-01-28
TW201245225A (en) 2012-11-16
JP2014513953A (ja) 2014-06-19

Similar Documents

Publication Publication Date Title
MA35035B1 (fr) Anticorps polypeptidiques qui antagonisent les cd40
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA45029A (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA40035A (fr) Molécules d'anticorps de pd-l1 et leurs utilisations
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA38478A1 (fr) Anticorps anti-pac1 humains
PE20141151A1 (es) Proteinas de union al antigeno cd27l
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA31821B1 (fr) Anticorps anti-cxcr5 humanises, leurs derives et leurs utilisations
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
WO2019032945A9 (fr) Agent liant cd40 et utilisations associées
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
MA37317B1 (fr) Formulation d'anticorps il-17
MA38161A1 (fr) Anticorps anti-bmp-6
PE20141706A1 (es) Anticuerpos de union a trombina y usos del mismo
MA40968A (fr) Polythérapie à base d'anticorps anti-egfr
MA38501B1 (fr) Anticorps humains de la protéine f du virus respiratoire syncytial et ses procédés d'utilisation
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation